Liu Yaoping, Wang Wei
School of Integrated Circuits, Peking University, Beijing 100871, China.
Antimicrobial Resistance (AMR) and Critical Analytics for Manufacturing Personalized-Medicine (CAMP) IRGs, Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore 138602, Singapore.
Micromachines (Basel). 2022 Jan 28;13(2):209. doi: 10.3390/mi13020209.
Liquid biopsy, the technique used to shed light on diseases via liquid samples, has displayed various advantages, including minimal invasiveness, low risk, and ease of multiple sampling for dynamic monitoring, and has drawn extensive attention from multidisciplinary fields in the past decade. With the rapid development of microfluidics, it has been possible to manipulate targets of interest including cells, microorganisms, and exosomes at a single number level, which dramatically promotes the characterization and analysis of disease-related markers, and thus improves the capability of liquid biopsy. However, when lab-ready techniques transfer into hospital-applicable tools, they still face a big challenge in processing raw clinical specimens, which are usually of a large volume and consist of rare targets drowned in complex backgrounds. Efforts toward the sample preparation of clinical specimens (i.e., recovering/concentrating the rare targets among complex backgrounds from large-volume liquids) are required to bridge the gap between the proof-of-concept demonstrations and practical applications. The throughput, sensitivity, and purity (TSP performance criteria) in sample preparation, i.e., the volume speed in processing liquid samples and the efficiencies of recovering rare targets and depleting the backgrounds, are three key factors requiring careful consideration when implementing microfluidic-based liquid biopsy for clinical practices. Platforms based on a single microfluidic module (single-modal microfluidics) can hardly fulfill all the aforementioned TSP performance criteria in clinical practices, which puts forward an urgent need to combine/couple multiple microfluidic modules into one working system (i.e., multi-modal microfluidics, M) to realize practically applicable techniques for the sample preparation of liquid biopsy. This perspective briefly summarizes the typical microfluidic-based liquid biopsy techniques and discusses potential strategies to develop M systems for clinical practices of liquid biopsy from the aspect of sample preparation.
液体活检是一种通过液体样本揭示疾病的技术,已展现出诸多优势,包括微创性、低风险以及便于多次采样进行动态监测等,在过去十年中受到了多学科领域的广泛关注。随着微流控技术的迅速发展,已能够在单个细胞水平上操控包括细胞、微生物和外泌体在内的目标物,这极大地促进了疾病相关标志物的表征与分析,从而提升了液体活检的能力。然而,当实验室可用技术转化为适用于医院的工具时,在处理原始临床样本方面仍面临巨大挑战,这些样本通常体积庞大,且由淹没在复杂背景中的稀有目标物组成。需要努力进行临床样本的制备(即从大量液体的复杂背景中回收/富集稀有目标物),以弥合概念验证演示与实际应用之间的差距。样本制备中的通量、灵敏度和纯度(TSP性能标准),即处理液体样本的体积速度以及回收稀有目标物和去除背景的效率,是在将基于微流控的液体活检应用于临床实践时需要仔细考虑的三个关键因素。基于单个微流控模块的平台(单模态微流控)在临床实践中很难满足上述所有TSP性能标准,这迫切需要将多个微流控模块组合/耦合到一个工作系统中(即多模态微流控,M),以实现适用于液体活检样本制备的实用技术。本文简要总结了典型的基于微流控的液体活检技术,并从样本制备的角度讨论了开发用于液体活检临床实践的M系统的潜在策略。